title: New developments in hormonal therapy for acne.
abstract: Oral contraceptives (OCs) are a valuable option for the treatment of women with acne. The use of OCs can be considered across the spectrum of acne disease severity in women. In Canada, three preparations are approved for mild-to-moderate acne, and a fourth is indicated for severe acne. These formulations contain estrogen in the form of ethinyl estradiol and a progestin. In Canada, the most recently approved OC is ethinyl estradiol 0.03 mg and drospirenone 3mg (Yasmin, Bayer). With the accumulating evidence on the efficacy and safety of drospirenone-containing hormonal preparations, this formulation provides dermatologists with a new treatment option for acne and other hyperandrogenic disorders.
authors.affiliation: Department of Medicine, University of Western Ontario, London, ON, Canada Windsor Clinical Research Inc, Windsor, ON, Canada.
authors.forename: J K L
authors.initials: JK
authors.lastname: Tan
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000736:Androstenes / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000627:therapeutic use; D009644:Norgestrel / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000736:Androstenes; D003278:Contraceptives, Oral, Hormonal; D009644:Norgestrel; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D016912:Levonorgestrel; C017576:norgestimate; C035144:drospirenone